Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

References

• LandiLCappuzzoFIrreversible EGFR-TKIs: dreaming perfectionTransl Lung Cancer Res201321404925806203
   PubMedGoogle Scholar
• OuRomanidouLandiLCappuzzoFCalifanoROvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerTher Adv Med Oncol20168317618727239236
   PubMed Web of Science ®Google Scholar
• NCCN GuidelinesNon-small cell lung cancer (Version 4)2016 Available from 1) https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed July 12, 2017
   Google Scholar
• CappuzzoFGuide to Targeted Therapies: Treatment Resistance in Lung CancerAdis-SpringerSwitzerland2015
   Google Scholar
• JännePAYangJames Chih-HsinKimDong-WanAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Engl J Med20153721689169925923549
   PubMed Web of Science ®Google Scholar
• YangJCAhnMJKimDWOsimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension componentJ Clin Oncol201735121288129628221867
   PubMed Web of Science ®Google Scholar
• MitsudomiTTsaiCShepherdFAZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II studyJ Thorac Oncol2015109 Suppl 2S320 n.d
   Web of Science ®Google Scholar
• MokTSWuYLAhnMJOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancerN Engl J Med2017376762964027959700
   PubMed Web of Science ®Google Scholar
• JackmanDPaoWRielyGClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol201028235736019949011
   PubMed Web of Science ®Google Scholar
• HaYuArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancerClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• ChabonJJSimmonsADLovejoyAFCirculating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanism in lung cancer patientsNat Commun201671181527283993
   PubMed Web of Science ®Google Scholar
• RosellRKarachaliouNImplications of blood-based T790M genotyping and beyond in epidermal growth factor receptor-mutant non-small-cell lung cancerJ Clin Oncol201634283361336227432918
   PubMed Web of Science ®Google Scholar
• OxnardGRThressKSAldenRSAssociation between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancerJ Clin Oncol201634283375338227354477
   PubMed Web of Science ®Google Scholar
• CrossDAAshtonSEGhiorghiuSAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerCancer Discov2014491046106124893891
   PubMed Web of Science ®Google Scholar
• JännePAYangJC-HKimD-WAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Engl J Med2015372181689169925923549
   PubMed Web of Science ®Google Scholar
• KhozinSWeinstockCBlumenthalGMOsimertinib for the treatment of metastatic epidermal growth factor T790M positive non-small cell lung cancerClin Cancer Res2017239
   Web of Science ®Google Scholar
• OmuroAMKrisMGMillerVAHigh incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinibCancer20051032344234815844174
   PubMed Web of Science ®Google Scholar
• Jamal-HanjaniMSpicerJEpidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brainClin Cancer Res201218493894422167408
   PubMed Web of Science ®Google Scholar
• BallardPYatesJWYangZPreclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityClin Cancer Res201622205130514027435396
   PubMed Web of Science ®Google Scholar
• YangJC-HKimD-WKimS-WOsimertinib activity in patients (pts) with leptomeningeal (LM) disease from nonsmall cell lung cancer (NSCLC): updated results from BLOOM, a phase I studyJ Clin Oncol201634Suppl9002
   Web of Science ®Google Scholar
• RamalingamSRukazenkovYThomasetKA randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. Abstract. Meetinglibrary. asco.orgASCO Annual Meeting2015 Abstract number TPS8102
   Google Scholar
• OxnardGRRamalingamSSAhnM-JPreliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancerASCO Meeting Abstracts2015332509
   Google Scholar
• LiaoBCLinCCLeeJHYangChih-HsinUpdate on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptors tyrosine kinase inhibitorsJ Biomed Sci2016238627912760
   PubMed Web of Science ®Google Scholar
• Broderick JMClovis ends development of rociletinib in lung cancer OncLive.com. Published Online: Friday, May 6, 2016. Available from http://www.onclive.com/web-exclusives/clovis-ends-development-of-rociletinib-in-lung-cancerAccessed July 18, 2017
   Google Scholar
• Clovis Oncology announces regulatory update for rociletinib NDA filingBusiness Wire11162015 Available from http://www.business-wire.com/news/home/20151116005513/en/Clovis-Oncology-Announces-Regulatory-Update-Rociletinib-NDAAccessed July 18, 2017
   Google Scholar
• WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol201693427071706
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med20153731627163926412456
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med201537312313526028407
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumabversus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trialLancet20163871540155026712084
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet20163871837184626970723
   PubMed Web of Science ®Google Scholar
• BarlesiFParkKCiardelloFPrimary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLCAnn Oncol201627Suppl. 6vi552vi587
   Google Scholar
• ReckMRodriguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med20163751823183327718847
   PubMed Web of Science ®Google Scholar
• LinKChengJYangTLiYZhuBEGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kBBiochem Biophys Res Commun201546395101
   PubMed Web of Science ®Google Scholar
• RizviNAChowLQMBorghaeiHSafety and response with nivolumab (anti-D1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. Vol. 32ASCO Meeting Abstracts20148022
   Google Scholar
• CreelanBCChowLQKimDWSafety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). Vol. 33ASCO Meeting Abstracts20153047
   Google Scholar
• RemonJBesseBUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsESMO Open201614e00008127843631
   PubMedGoogle Scholar
• MaWGilliganBMYuanJLiTCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyJ Hematol Oncol201694727234522
   PubMed Web of Science ®Google Scholar
• SoniaJCWuYLNakagawaKGefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialLancet Oncol20151699099826159065
   PubMed Web of Science ®Google Scholar
• WeickhardtAJScheierBBurkeJMLocal ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancerJ Thorac Oncol201271807181423154552
   PubMed Web of Science ®Google Scholar
• EskensFAMomCHPlantingASA phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursBr J Cancer200898808518026190
   PubMed Web of Science ®Google Scholar
• JanjigianYYSmithEFGroenHJDual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsCancer Discov201441036104525074459
   PubMed Web of Science ®Google Scholar
• WangSSongYLiuDEAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistanceCancer Lett2017385515427840244
   PubMed Web of Science ®Google Scholar
• YuHATianSKDrilonAEAcquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domainJAMA Oncol20151798298426181354
   PubMed Web of Science ®Google Scholar
• ThressKSPaweletzCPFelipEAcquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MNat Med201521656056225939061
   PubMed Web of Science ®Google Scholar
• WoyachJAFurmanRRLiuTMResistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinibN Engl J Med20143702286229424869598
   PubMed Web of Science ®Google Scholar
• WangSTsuiSTLiuCSongYLiuDEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerJ Hematol Oncol201695927448564
   PubMed Web of Science ®Google Scholar
• LeeYJChoiHJKimSKFrequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patient with nonsmall-cell lung cancerCancer20101161336134320066717
   PubMed Web of Science ®Google Scholar
• HellmanMDGettingerSNGoldmanJWCheckmate 012: safety and efficacy of first-line nivolumab and ipilimumab in advanced NSCLCASCO Meeting Abstracts20163415_suppl3001
   Google Scholar
• AntoniaSGoldbergSBBalmanoukianASafety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyLancet Oncol201617329930826858122
   PubMed Web of Science ®Google Scholar
• DholariaBHammondWShredersALouYEmerging therapeutic agents for lung cancerJ Hematol Oncol2016913827938382
   PubMed Web of Science ®Google Scholar
• MokTSWuYIThongprasertSGefitinib or Carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol2012301122112822370314
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trialLancet Oncol20101112112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarceremyEGervaisRErlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR-mutation positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trialLancet Oncol20121323924622285168
   PubMed Web of Science ®Google Scholar
• WuYLLiamCKZhouCFirst-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): interim analyses from the phase 3, open-label, ENSURE studyJ Thorac Oncol20138s603 Suppl.2
   Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol2013313327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutation (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol20141521322224439929
   PubMed Web of Science ®Google Scholar